[Featured Stock] Hanall Biopharma Shows Early Strength on New Drug Development Hopes

HanAll Biopharma is showing strong performance in the early trading session on the 6th. This is interpreted as investor sentiment being driven by expectations for new drug development.

As of 9:20 AM on the 6th, HanAll Biopharma is trading at 44,650 KRW, up 4,000 KRW (9.84%) compared to the previous trading day.

Recently, global pharmaceutical market research firm Evaluate Pharma announced the ‘Top 10 Promising R&D Projects of the Year,’ in which HanAll Biopharma’s new drug candidates from its partner Immunovant (Roivant), ‘IMVT-1402’ and ‘Batoclimab (IMVT-1401),’ were ranked 5th and 6th respectively.

Both IMVT-1402 and Batoclimab are new drugs jointly developed by HanAll Biopharma and its partner Immunovant. In particular, IMVT-1402 has the potential to become a First-in-Class drug in its category. Immunovant is conducting clinical trials targeting Graves’ Disease (GD), Rheumatoid Arthritis (RA), and Myasthenia Gravis (MG).

Clinical Phase 3 results for Myasthenia Gravis and Thyroid Eye Disease are expected to be announced in the first and second quarters of this year, respectively.

Additionally, HanAll Biopharma’s Parkinson’s disease treatment candidate HL192 showed positive results in Phase 1 clinical trials. The dry eye treatment ‘HL036,’ jointly developed with Daewoong Pharmaceutical, entered its third Phase 3 clinical trial last year, aiming to produce topline results by 2026.